Investigational drug · Phase 2
PRT-064040
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Migraine.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "PRT-064040"
First trial start
2026
Jan 26, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PRT-064040", any sponsor or status.
Conditions studied
As listed on its trial records.
- Migraine
Approved drugs for the same conditions: Migraine · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "PRT-064040" as an intervention, largest first.
- Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in AdultsPivotal-lookingRecruiting
Sichuan Purity Pharmaceutical Technology Co., Ltd.Industry
NCT07304518 · 456 participants (planned) · Start Jan 26, 2026 · Primary completion Sep 2026
Drug: PRT-064040 nasal spray; Placebo · For: Migraine
Sites: Beijing, China
Sichuan Purity Pharmaceutical Technology Co., Ltd.Industry
NCT07016516 · 80 participants · Start Jun 7, 2025 · Primary completion Sep 8, 2025
Drug: PRT-064040 nasal spray; Placebo and 2 more · For: Migraine
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- PRT-064040: A nasal spray of novel, potent, and selective calcitonin gene-related peptide receptor antagonist for migraine.
Du S, Yang H, Yue J, et al. · J Pharmacol Exp Ther 2026
Also in development for Migraine
- AXS-07meloxicam-rizatriptanPhase 31 trial
Axsome Therapeutics, Inc. · Migraine
- EVO756Phase 24 trials
Evommune, Inc. · Migraine, Chronic Inducible Urticaria, Atopic Dermatitis
- BHV-2100Phase 21 trial
Biohaven Therapeutics Ltd. · Migraine
- MEDI0618Phase 21 trial
AbbVie · Migraine
- MTX101Phase 21 trial
Manistee Therapeutics · Migraine
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.